Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
Atara Biotherapeutics, Inc. (ATRA)
Last atara biotherapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.atarabio.com/investor-relations
Company Research
Source: Business Wire
Pierre Fabre to Commercialize Tab-cel® for Epstein-Barr Virus (EBV)-Positive Cancers in Europe, Middle East, Africa, and Other Select Emerging MarketsAtara to Receive Upfront Payment of USD 45 Million, and Up to Approximately USD 320 Million in Total Milestones, Plus Significant Double-digit Tiered Royalties as a Percentage of Net SalesAtara Retains Full Commercialization Rights to Tab-cel® in the United States and Other Major MarketsTab-cel®, Recently Granted EMA Accelerated Assessment, Remains On-Track for European MAA Filing in November 2021Atara to Host Conference Call on Monday, October 4 at 8:30 a.m. EDT SOUTH SAN FRANCISCO, Calif. & CASTRES, France--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced an exclusive commercialization agreement for tabelecleucel (tab-cel®) in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus (EBV)-positive cancers. Atara will retain full rights to tab-cel® in other majo
Show less
Read more
Impact Snapshot
Event Time:
ATRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATRA alerts
High impacting Atara Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ATRA
News
- Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress [Yahoo! Finance]Yahoo! Finance
- Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational ProgressBusiness Wire
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
ATRA
Earnings
- 5/9/24 - Beat
ATRA
Analyst Actions
- 4/1/24 - Stifel
ATRA
Sec Filings
- 5/10/24 - Form DEFR14A
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- ATRA's page on the SEC website